Fenwick represented Nurix Therapeutics, Inc. (NASDAQ: NRIX), a company developing targeted protein modulation drugs, in its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix, were $209 million.
J.P. Morgan, Piper Sandler and Stifel acted as joint bookrunning managers for the proposed offering. Needham & Company acted as lead manager.
More information about the offering can be obtained from Nurix’s announcement.
The Fenwick transaction team included corporate partners Michael Brown, Amanda Rose and Robert Freedman, and associates Jennifer Hitchcock, Katherine Duncan, Annie Omata and Alyssa Zhang; as well as executive compensation & employee benefits partner Elizabeth Gartland and associate Corinne Nhaissi.